Biotech company Willow Biosciences Inc. (TSX:WLLW) (OTCQB:CANSF) generated nearly $1.3 million in revenues in 2023, increasing approximately 60% over the period. Dr. Chris Savile, president and CEO of the company called 2023 a “transformative year for Willow,” which relies on synthetic biology techniques to create compounds like cannabigerol typically extracted from cannabis. Why? In its Wednesday press release, the company said one of its top achievements over the past 12 months was the launch of BioOxi bio-oxidation platform technology. The AI-driven selective hydroxylation platform has been…